Novogen.

Beiträge: 20
Zugriffe: 8.518 / Heute: 1
Novogen ADR kein aktueller Kurs verfügbar
 
Eskimato:

Novogen.

 
22.05.03 17:59
Ich hab die Aktie schon zweimal vorgestellt, baani wird sich an die "australische Macropore" erinnern.
Jetzt von 4 auf 15,60 mittlerweile, ist doch was.

Gruss E.

chart.bigcharts.com/bc3/quickchart/...32&mocktick=1&rand=5835"

Werbung

Entdecke die beliebtesten ETFs von SPDR

SPDR MSCI World Communication Services UCITS ETF
Perf. 12M: +48,78%
SPDR S&P U.S. Communication Serv. Select Sector UCITS ETF Ac
Perf. 12M: +46,72%
SPDR MSCI World Technology UCITS ETF
Perf. 12M: +43,10%
SPDR S&P U.S. Consumer Discretionary Select Sector UCITS ETF
Perf. 12M: +42,59%
SPDR S&P U.S. Financials Select Sector UCITS ETF
Perf. 12M: +41,98%

Eskimato:

Public Offering

 
07.10.03 07:57
von MSHL für NVGN-Holder: (MSH in London auf ATH)

Gruss E.

Marshall Edwards Inc. Announces Intent to List Company on NASDAQ SmallCap And Initial Public Offering of Two Million Common Stock Units  
       THURSDAY, SEPTEMBER 25, 2003 5:46 PM
- PR Newswire

WASHINGTON, Sep 25, 2003 /PRNewswire-FirstCall via COMTEX/ -- Pharmaceutical company Marshall Edwards, Inc. announced today that it filed a registration statement with the Securities Exchange Commission for the initial public offering of 2,000,000 common stock units, each unit consisting of one share of its common stock and a warrant to purchase one share of its common stock. It is anticipated that each common stock unit will be offered in the price range of $4.50 to $6.50. The company said it has also applied for a NASDAQ SmallCap listing under the symbol MSHL.

Up to 1,500,000 of the 2,000,000 common stock units will be offered by subscription to U.S. holders of Novogen Limited (NVGN) American Depository Receipts (ADRs), U.S. holders of Novogen shares (ASX: NRT), as well as U.S. holders of Marshall Edwards, Inc. common stock as of a date to be determined by the Board of Directors of Marshall Edwards, Inc. Novogen Limited is not participating in the offering.

Janney Montgomery Scott LLC will be the underwriter with respect to 500,000 common stock units and any common stock units not purchased in connection with the subscription program. When available, a preliminary prospectus relating to these securities may be obtained from Janney Montgomery Scott LLC, at 1801 Market Street, Philadelphia, Pennsylvania 19103.

A registration statement relating to these securities has been filed with the Securities Exchange Commission but has not yet become effective. These securities may not be sold nor may any offer to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

About Marshall Edwards

Marshall Edwards is a pharmaceutical company focused on the development and commercialization of therapies to treat patients with various forms of cancer. Marshall Edwards, Inc is currently listed on the London Stock Exchange's Alternative Investment Market under the symbol MSH.

CONTACT: US-Australia: Mr. Christopher Naughton, President and CEO of Marshall Edwards, Inc., + 61.2.9878 0088

SOURCE Marshall Edwards, Inc.

US-Australia: Mr. Christopher Naughton, President and CEO of
Marshall Edwards, Inc., +61-2-9878-0088
(NVGN)


Copyright (C) 2003 PR Newswire. All rights reserved.

Eskimato:

Novogen stärkster Wert im ASX 200.

 
29.10.03 07:50
Wo wir doch auch gelegentlich Ausflüge nach Australien unternehmen.

Gruss E.
Eskimato:

Sag Hallo zu 28 Dollar bei Novogen.

 
07.11.03 20:38
Langsam aber sicher ernährt sich das Eichhörnchen.

Gruss E.
xnomis:

NVGN own 87% of MSHL

 
28.07.11 08:47
MSHL mcap 20mio
NVGN mcao 20mio

MHSL hat ca. 2mio shares freefloat. gestern ca 11.mio gehandelt, davon massig short.
Schon mal an die Squeeeez von VW gedacht ?

Topspekulation today!

Remember SINO vor ein paar Tagen.
xnomis:

MSHL + 136%

 
28.07.11 08:48
Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells

tweet0EmailPrintCompanies:Marshall Edwards Inc. Related Quotes
Symbol Price Change
MSHL 2.75 +1.58

{"s" : "mshl","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: Marshall Edwards, Inc. On Wednesday July 27, 2011, 9:00 am EDT
SAN DIEGO, July 27, 2011 /PRNewswire/ -- Marshall Edwards, Inc.(Nasdaq:MSHL - News), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced the publication of results from a pre-clinical study of NV-128 showing activity in chemotherapy-resistant ovarian cancer stem cells. NV-128 is the prodrug of the Company's investigational compound and lead mitochondrial inhibitor drug candidate, NV-344. The publication, entitled "Targeting the mitochondria activates two independent cell death pathways in the ovarian cancer stem cells," is available on the Molecular Cancer Therapeutics website and scheduled to print in the August issue of the journal. An abstract can be found at www.marshalledwardsinc.com/our-programs/scientific-publications.

"A major obstacle in the successful treatment of ovarian cancer is disease recurrence due in part to the outgrowth of chemotherapy-resistant ovarian cancer stem cells," said senior author Gil Mor, M.D., Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine. "This study shows that NV-128 can specifically target the mitochondriain patient-derived ovarian cancer stem cells to induce cell death in an otherwise chemo-resistant cell population. We believe these encouraging data provide sufficient proof of concept to warrant further study in ovarian cancer patients."

Previous studies conducted at Yale University showed that NV-128 is able to inhibit tumor growth in an ovarian cancer animal model without inducing significant toxicity, suggesting a sufficient therapeutic window that may allow compounds of this class to be safely administered to patients. Once administered, NV-128 is demethylated in vivo to NV-344, its active metabolite, which has been shown to be significantly more potent than NV-128 in pre-clinical research studies. Marshall Edwards plans to complete the required pre-clinical studies of NV-344 to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) by the first quarter of 2012.

"This study exemplifies the importance of our ongoing collaboration with Dr. Mor and his associates at Yale University as well as our continuing commitment to enhancing our pipeline of novel drug candidates," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of Marshall Edwards. "We are excited about the progress we are making with both of our lead candidates, NV-143 and NV-344, and look forward to reporting on their clinical development in the months ahead."

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq:MSHL - News) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead drug candidate NV-143. The second is a mitochondrial inhibitor program that includes lead candidate NV-344. The Company expects to initiate a Phase I clinical trial of intravenous NV-143 in September 2011, followed by randomized Phase II trials in combination with chemotherapy. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
Balu4u:

Hammmer!

 
20.02.13 12:17
6,47 USD+4,36 USD+206,64 %

 

wes_:

was zum?

 
20.02.13 18:38
wes_:

hot

 
20.02.13 18:39
$ 9,12 (USD)
Balu4u:

???

 
18.03.15 13:56
iwanooze:

news!

 
17.04.15 13:04
www.prnewswire.com/news-releases/...rain-cancer-300067680.html
Androlyt:

noch jemand dabei?

 
09.03.17 14:47
ist ja sehr ruhig geworden um Novogen..Wann gibts den nächsten Ausspruch?
JOtheViper:

Hab das Ding schon länger

 
22.04.17 09:34
auf dem Schirm. Ist sehr ruhig geworden um diese Aktie. Dieses Jahr sollen jedoch News kommen. Bin gespannt.

Grüße  
Androlyt:

Seit dem

 
23.04.17 00:28
Leute aus dem Führungsteam das Unternehmen verlassen haben und eine Studie GDC-0084 eingestellt wurde habe ich mich erstmal zurück gezogen von Novogen.Ist leider nicht mehr der Shotingstar wie 2015..
JOtheViper:

Nächste Woche

 
12.05.17 23:45
könnte interessant werden.  :-)
Androlyt:

Warum

 
13.05.17 21:19
JOtheViper:

NVGN ist auch vertreten

 
15.05.17 08:58
www.asx.com.au/seminars/ceo-sessions/...ssions~Twitter~~201705
JOtheViper:

5 Jahre Chart

 
16.05.17 18:35
JOtheViper:

so jetzt aber...

 
16.05.17 18:38
(Verkleinert auf 59%) vergrößern
Novogen. 990134
Androlyt:

Da

 
16.05.17 23:20
gehen bald die Lichter aus..Für mich Strong Sell!
Es gibt keine neuen Beiträge.


Börsen-Forum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen

Neueste Beiträge aus dem Novogen ADR Forum

Wertung Antworten Thema Verfasser letzter Verfasser letzter Beitrag
  19 Novogen. Eskimato Androlyt 16.05.17 23:20

--button_text--